Sclerosing therapy in chronic Achilles tendon insertional XXXX -results of a pilot study.

@entity1 @entity924 @entity2631 @entity730 @entity158 @entity5324
The origin of Achilles tendon insertional @entity158 has not been clarified. Treatment is considered difficult, though tendon, bone, and bursae, alone or in combination, may all be the source of @entity158 . Recently, neovascularisation in the area with tendon changes was shown to correlate with @entity158 in @entity1 with chronic @entity924 . In a pilot study, sclerosing the neovessels outside the tendon cured the @entity158 in the majority of @entity1 . In this pilot-study, ultrasonography and colour Doppler was used for the investigation of eleven @entity1 (nine @entity1 and two @entity1 , mean age 44 years) with a long duration (mean 29 months) of chronic Achilles tendon insertional @entity158 . All @entity1 had distal tendon changes and a @entity2631 inside and outside the distal tendon on the injured/painful side, but not on the noninjured/ @entity158 -free side. In nine @entity1 there was also a thickened retrocalcaneal bursae, and in four @entity1 also bone pathology ( @entity730 , spur, loose fragment) in the insertion. The sclerosing agent @entity5324 was injected against the local neovessels found in all @entity1 . At follow-up (mean eight months), sclerosing of the area with neovessels had cured the @entity158 in eight out of eleven @entity1 , and in seven of the eight @entity1 there was no neovascularisation. @entity158 during tendon-loading activity, recorded on a VAS-scale, decreased from 82 mm before treatment to 14 mm after treatment in the successfully treated @entity1 . In conclusion, treatment only focusing on sclerosing the area with neovessels showed promising short-term clinical results in this small pilot study. The findings support further studies, preferably in a randomised manner.
